alphaveGLENMARK₹2,403.10

Glenmark Pharmaceuticals Ltd.

₹ CrorePeersDRREDDY LUPIN ALKEM BIOCON MANKIND LAURUSLABS FORTIS AUROPHARMAMcap ₹67,815 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	3,118.2	3,319.4	3,889.6	3,889.6
+ Capital Work-in-Progress	419.3	542.0	427.9	427.9
+ Goodwill	67.4	70.3	82.9	82.9
+ Other Intangibles	1,024.7	1,097.2	1,942.1	1,942.1
+ Intangibles under Development	242.6	292.8	481.3	481.3
+ Non-current Investments	789.7	56.4	42.4	42.4
+ Long-term Loans	0.0	0.0	67.5	67.5
+ Other Non-current Financial Assets	69.9	72.9	—	—
Non-current Financial Assets	859.5	129.3	109.9	109.9
+ Deferred Tax Assets	1,049.7	1,124.1	1,246.6	1,246.6
+ Other Non-current Assets	149.2	179.0	428.0	428.0
Total Non-current Assets	6,930.5	6,754.1	8,608.2	8,608.2
Current Assets
+ Inventories	2,513.1	3,028.5	3,430.8	3,430.8
+ Trade Receivables	1,858.4	3,341.9	4,963.4	4,963.4
+ Cash & Cash Equivalents	1,658.3	1,675.7	1,174.7	1,174.7
+ Other Bank Balances	1.2	29.5	1.5	1.5
+ Other Current Financial Assets	173.6	62.4	224.7	224.7
Current Financial Assets	3,691.5	5,109.6	6,364.3	6,364.3
+ Other Current Assets	1,223.6	1,157.3	1,504.6	1,504.6
Total Current Assets	7,428.1	9,295.5	11,299.7	11,299.7
Total Assets	14,358.6	16,049.6	19,907.9	19,907.9
Equity
+ Equity Share Capital	28.2	28.2	28.2	28.2
+ Other Equity / Reserves	7,819.7	8,821.2	10,483.9	10,483.9
Equity — Owners of Parent	7,847.9	8,849.4	10,512.1	10,512.1
+ Minority Interest	-0.4	-0.4	-0.3	-0.3
Total Equity	7,847.5	8,849.1	10,511.8	10,511.8
Liabilities
+ Borrowings — Non-current	0.0	512.7	0.0	0.0
+ Other Non-current Financial Liab	538.8	662.2	1,482.3	1,482.3
Non-current Financial Liabilities	690.5	1,174.9	1,482.3	1,482.3
+ Deferred Tax Liabilities	0.3	58.6	1.2	1.2
+ Other Non-current Liabilities	1.7	0.0	1,536.1	1,536.1
Non-current Liabilities	692.5	1,233.5	3,019.7	3,019.7
+ Borrowings — Current	990.6	1,681.5	0.0	0.0
+ Trade Payables	2,535.9	2,579.5	3,743.9	3,743.9
+ Other Current Financial Liab	1,115.6	882.5	605.8	605.8
Current Financial Liabilities	4,642.1	5,143.6	4,349.7	4,349.7
+ Provisions — Current	641.1	596.1	1,070.1	1,070.1
+ Current Tax Liabilities	291.0	28.4	94.5	94.5
+ Other Current Liabilities	244.4	199.0	862.1	862.1
Current Liabilities	5,818.6	5,967.0	6,376.4	6,376.4
Total Liabilities	6,511.1	7,200.5	9,396.1	9,396.1
Total Equity & Liabilities	14,358.6	16,049.6	19,907.9	19,907.9
Assets — additional as-filed lines
+ Current Tax Assets	0.0	1,157.3	0.0	0.0
Liabilities — additional as-filed lines
+ Trade Payables — Non-current	151.7	0.0	—	—
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	21.4	23.1	23.1
+ Dues to Other Creditors — Current	—	2,558.1	3,720.8	3,720.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.